Radioimmunodetection of prostate cancer by 111In-labeled monoclonal antibody against prostatic acid phosphatase.
Purified human prostate acid phosphatase (PAP) was used to generate a specific monoclonal antibody (FC 3001) for detection of PAP expressed by some prostatic carcinomas. DTPA derivatives of MoAb-F(ab')2-fragments were labeled with indium-111 chloride. This labeled antibody was tested in 15 prostate cancer patients who underwent staging pelvic lymphadenectomy; 9 of them received labeled antibody alone whereas 6 received simultaneous injections of labeled and unlabeled antibody with two dose levels (40 or 80 mg). Biodistribution data obtained by direct blood measurements and imaging procedures indicated that simultaneous injection of unlabeled antibody reduced both the blood elimination rate and the accumulation in the liver. Accumulation of the radionuclide in pelvic lymph node metastases was observed in some patients but in a couple of patients accumulation was noted also in normal lymph nodes. The method cannot in its present design replace staging pelvic lymphadenectomy and further studies are needed for elaboration of clinically useful radioimmunodetection methods.
Ahonen
A
A
Department of Nuclear Medicine, Turku University Central Hospital, Finland.
Kairemo
K
K
Karnani
P
P
Heikkilä
J
J
Nurmi
M
M
Teräs
M
M
Lukkarinen
O
O
D000135:Acid Phosphatase / Q000276:immunology*; D000911:Antibodies, Monoclonal; D006801:Humans; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging; D011467:Prostate / Q000201:enzymology*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D016719:Radioimmunodetection; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D000135:Acid Phosphatase